GRANTS / FUNDING
Funding for Phase 1 & 2
WP1122 has received nearly $2 million in grants and has had over $1 in development dollars invested in furthering the technology and expects to spend over $2 million in the next 24 months on Phase I and Phase II clinical trials.
WP1122 expected to have a completed IND and begin clinical trials in 2019
DRUG DISCOVERY & DEVELOPMENT
UT MD Anderson Cancer Center
Ranked in the USA as No 1 cancer treatment and research center and the leading institution in the world, drug discovery.
Moleculin Biotech, Inc.
University of Bergen, Norway
ALS through its development partner has shown in preclinical trials that WP1122 performed as well or better than temozolomide, a drug that is a standard of care for the treatment of glioblastoma.
Pancreatic Cancer & Glioblastoma. Combination with radiotherapy
A combination of WP1122 with cytotoxic agents should produce significantly enhanced anticancer effects in a wide range of cancers.